Imspex Diagnostics’ proprietary GC-IMS analytical technology platform has built a legacy of being a versatile, accurate and robust analytical research tool in situations where compound combinations are complex and/ or concentrations are low. Much of this legacy has centred around volatile compounds in industrial and more recently environmental and food production settings.
The ultra-highly sensitive combination of gas chromatography (GC) and Ion Mobility Spectrometry (IMS) technologies also means that this platform is uniquely suited to be used as a point-of-care diagnostic device in day-to-day medical and healthcare situations where non-invasive sampling and quick test turnaround are needed for early diagnosis leading to more effective treatment.
The Board of Imspex Diagnostics Ltd recognises that breath analysis can fill this gap and has set up a dedicated Imspex Medical team to steer the process of taking GC-IMS technology into these medical and healthcare settings.
Start-up specialist, Dr Michael Graz, and Imspex Diagnostics Limited’s CEO, Santi Dominguez will lead this expansion, advised and assisted by an experienced commercial and regulatory team. Imspex Medical’s initial target will be to make the GC-IMS technology available for use in detecting infection with SARS-CoV-2 as part of the global effort to reopen communities and economies.
The GC-IMS platform already has proven capability in differentiating between bacterial and viral respiratory infections as well as detecting a range of other infectious and inflammatory diseases and cancers. More details of follow-on targets can be found on Imspex Medical’s website www.imspexmedical.com.
Contact the team at email@example.com